The role of leukotrienes and prostaglandins in development of atopy has been prototypically established in studies of asthma pathogenesis. Likewise, both in vitro and in vivo studies of atopic dermatitis have demonstrated that these molecules maintain important pathophysiologic roles. Thus, it follows that targeted therapies against these molecules may be promising in management of atopic dermatitis. Montelukast has had questionable efficacy in patients with atopic dermatitis, while small pilots using zileuton did have some clinically significant improvement. There are several agents in development that target leukotrienes and/or prostaglandins as well, including OC000459, Q301, and ZPL-521. In atopic dermatitis, OC000459 did not demonstrate efficacy in clinical trials, and the efficacy of the other two agents remains to be seen. Should these medications prove promising, these topical agents may play a future role in chronic maintenance therapy and flare prophylaxis in atopic dermatitis, as anti-leukotriene therapy does in asthma.

在哮喘发病机理的研究中已经典型地建立了白三烯和前列腺素在特应性发展中的作用。同样，对特应性皮炎的体外和体内研究均表明，这些分子保持重要的病理生理作用。因此，随之而来的是，针对这些分子的靶向疗法在特应性皮炎的治疗中可能是有希望的。孟鲁司特在特应性皮炎患者中的疗效令人怀疑，而使用齐留通的小型飞行员确实在临床上有明显改善。有几种靶向白三烯和/或前列腺素的药物正在开发中，包括OC000459，Q301和ZPL-521。在特应性皮炎中，OC000459在临床试验中未显示出疗效，其他两种药物的疗效仍有待观察。